Take what Bob says with a grain of salt. He’s a salesman, no medical or scientific background. Hence he forms his judgements based on what the board or investigators advise him. His primary objective is to fast track IBX to commercialisation.
We’re conducting our first clinical human trial with stringent guidelines and requirements on eligibility as per stated by ANZCTR. Not to mention we’re living in a pandemic. Can’t always use that excuse but I’m definitely sure it has exacerbated to some extent. Why do you think PAB is experiencing the same issue?
1c in 3 years is a joke, they have other pipeline of products in the works right now which will prevent the SP from dipping that low. 3 years is a long time for IBX to get their act together....
And if they were to suddenly stop trials here in Oz and start in say the US, imagine the administration, setting up costs, approvals, ethics and safety concerns, more delays, more cash burn. List goes on lol. I don’t think they’re willing to do that IMO.
IBX Price at posting:
7.0¢ Sentiment: None Disclosure: Held
(20min delay)